Skip to main content

AbbVie vs Novartis: Founders, CEOs and History

AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Novartis was founded in 1996 by Daniel Vasella, Alex Krauer and is led by Vasant Narasimhan.

Company facts

AbbVie

Founded
2013
Headquarters
North Chicago, Illinois
Current CEO
Robert A. Michael
Employees
57,000

Novartis

Founded
1996
Headquarters
Basel, Switzerland
Current CEO
Vasant Narasimhan
Employees
75,267

Founders

AbbVie

  • Abbott Laboratories (spin-off origin)

    Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.

AbbVie founders in full

Novartis

  • Daniel Vasella

    Novartis was formed in December 1996 when Ciba-Geigy and Sandoz merged in a deal valued at roughly $27 billion, then among the largest corporate mergers on record.

  • Alex Krauer

    Alex Krauer was the first chairman of Novartis, serving from the company's formation through the roughly $27 billion merger of Ciba-Geigy and Sandoz in 1996 until 1999, when the board named CEO Daniel Vasella to replace him as chairman.

Novartis founders in full

CEOs and their tenures

AbbVie

  1. Richard A. Gonzalez2013–2024

    Founding Chairman and Chief Executive Officer

    Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.

    Source
  2. Robert A. Michael2024–present

    Chairman and Chief Executive Officer

    Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.

    Source
AbbVie CEO history in full

Novartis

  1. Joseph Jimenez2010–2018

    Chief Executive Officer

    Serving as CEO from 2010 to 2018, he fundamentally transformed the massive Swiss conglomerate, heavily trimming its bloated divisions to create a highly focused, pure-play innovative medicines company.

    Source
  2. Vas Narasimhan2018–present

    Chief Executive Officer

    Narasimhan, a physician who previously led global drug development, became CEO on February 1, 2018.

    Source
  3. Giovanni Caforio2025–present

    Chair of the Board

    As a highly influential Board Member (and former BMS CEO), he brings unmatched global oncology expertise to Novartis's executive committee.

    Source
  4. Mukul Mehta2026–present

    Chief Financial Officer

    As CFO, he aggressively deploys massive amounts of capital toward high-risk, high-reward biotech acquisitions, ensuring Novartis maintains a dominant pipeline of blockbuster drugs.

    Source
Novartis CEO history in full

Timeline: AbbVie and Novartis side by side

  1. 1859Novartis

    Founding of Ciba

    Silk dyer Alexander Clavel began producing the synthetic dye fuchsine in Basel, Switzerland, marking the origin of Ciba, part of the Ciba-Geigy half of the Novartis merger.

  2. 1886Novartis

    Founding of Sandoz

    Alfred Kern and Edouard Sandoz founded the chemical company Kern & Sandoz in Basel, establishing the second half of the corporate lineage that would eventually merge to form Novartis.

  3. 1996Novartis

    Merger of Ciba-Geigy and Sandoz

    Ciba-Geigy and Sandoz completed their merger in December 1996, a deal valued at roughly $27 billion, creating Novartis AG.

  4. 2006Novartis

    Acquisition of Chiron Corporation

    Novartis acquired the US biotechnology company Chiron Corporation for $5.1 billion, significantly expanding its vaccine and oncology franchises.

  5. 2010Novartis

    Acquisition of Alcon

    Novartis completed the acquisition of the remaining stake in Alcon, the world's largest eye care company, for approximately $28 billion, creating a dominant position in ophthalmology.

  6. 2013AbbVie

    AbbVie Launches as an Independent Company

    AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.

  7. 2015AbbVie

    Pharmacyclics Acquisition Completed

    AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.

  8. 2015Novartis

    DOJ Settlement

    Novartis paid $390 million to resolve US allegations that it gave kickbacks to specialty pharmacies to promote Exjade and Myfortic.

  9. 2018Novartis

    Vas Narasimhan Appointed CEO

    Vas Narasimhan became CEO at age 41, one of the youngest leaders of a major pharmaceutical company, initiating a strategic review that would eventually lead to the Sandoz spin-off.

  10. 2019AbbVie

    Skyrizi Receives Initial U.S. Approval

    The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.

  11. 2019AbbVie

    Rinvoq Receives Initial U.S. Approval

    The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.

  12. 2020AbbVie

    Allergan Acquisition Completed

    AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.

  13. 2023AbbVie

    U.S. Humira Biosimilar Competition Begins

    Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.

  14. 2023Novartis

    Acquisition of Chinook Therapeutics

    Novartis acquired Chinook Therapeutics for $3.2 billion upfront plus $300 million in milestones, securing late-stage assets for rare kidney diseases.

  15. 2023Novartis

    Spin-off of Sandoz

    On October 4, 2023, Novartis completed the 100% spin-off of its Sandoz generics division, transforming into a pure-play innovative medicines company.

  16. 2024AbbVie

    ImmunoGen Acquisition Completed

    AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.

  17. 2024AbbVie

    Robert A. Michael Becomes CEO

    Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.

  18. 2024AbbVie

    Cerevel Therapeutics Acquisition Completed

    AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.

  19. 2024Novartis

    Acquisition of MorphoSys

    Novartis acquired German biotech MorphoSys for about EUR 2.7 billion ($2.9 billion), adding the investigational myelofibrosis drug pelabresib.

  20. 2025AbbVie

    Robert A. Michael Becomes Chairman

    Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.

  21. 2025AbbVie

    FY2025 Revenue Reaches $61.160 Billion

    AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.

  22. 2025Novartis

    FY2025 Financial Results

    Novartis reported FY2025 net sales of $54.5 billion, up 8%, with a core operating margin above 40% and free cash flow of $17.6 billion.

  23. 2025Novartis

    Entresto Generic Entry

    US generic versions of Entresto, Novartis's largest product, launched in 2025, starting the steepest patent cliff in the company's post-Sandoz history.

  24. 2026AbbVie

    Q1 2026 Revenue Reaches $15.002 Billion

    AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.

  25. 2026Novartis

    Avidity Biosciences Acquisition Closes

    On February 27, 2026, Novartis completed its roughly $12 billion acquisition of Avidity Biosciences, adding antibody-oligonucleotide conjugates for DM1, Duchenne and FSHD.

  26. 2026Novartis

    HARBOR Phase 3 Miss

    In September 2026, del-desiran missed the primary endpoint of the 159-patient Phase 3 HARBOR trial in myotonic dystrophy type 1, and NVS shares fell about 12.5% in pre-market trading.

Acquisitions

AbbVie

  • ImmunoGen, Inc.2024$10.1B
  • Cerevel Therapeutics2024$8.7B
  • Allergan plc2020$63B
  • Pharmacyclics, Inc.2015$21B
All AbbVie acquisitions

Novartis

  • Avidity Biosciences2026$12B
  • MorphoSys AG2024$2.9B
  • Chinook Therapeutics2023$3.5B
  • The Medicines Company2020$9.7B
  • Advanced Accelerator Applications2018$3.9B
  • Chiron Corporation2006$5.1B
All Novartis acquisitions

Questions about AbbVie vs Novartis

Who is the CEO of AbbVie Inc. and Novartis AG?

AbbVie Inc. is led by Robert A. Michael and Novartis AG is led by Vasant Narasimhan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was AbbVie Inc. founded vs Novartis AG?

Novartis AG was founded in 1996 — 17 years before AbbVie Inc., which was founded in 2013. Novartis AG's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..

How many employees does AbbVie Inc. have compared to Novartis AG?

AbbVie Inc. employs approximately 57,000 people, while Novartis AG employs approximately 75,267. Novartis AG has the larger workforce at 75,267 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are AbbVie Inc. and Novartis AG headquartered?

AbbVie Inc. is headquartered in United States and Novartis AG is headquartered in Switzerland. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.

Who founded AbbVie Inc. and Novartis AG?

AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Novartis AG was founded by Daniel Vasella, Alex Krauer.

Which company has a longer operating history — AbbVie Inc. or Novartis AG?

Novartis AG has been operating for approximately 30 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Novartis overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.